A call to bridge the gap between scientific discovery and community impact, urging a shift toward research that addresses domestic challenges and drives the nation towards development has been made to researchers and academics at the University of Nairobi at this year’s Research Week.
Stakeholders in the health sector have underscored the need for strategic collaboration within academia, industry and the government spheres of the sector in order to drive development and advance health in the country.
KAVI Institute of Clinical Research enrolled the first volunteer to start a phase 1 clinical trial to test a novel HIV vaccine candidate, BG505 SOSIP.664 gp140.
The study dubbed the International AIDS Vaccine Initiative W001 (IAVI W001) is aimed at assessing the safety of the candidate and to determine if vaccination induces the human immune system to produce proteins known as neutralizing antibodies (NAbs).
